Clinical and bacteriological characteristics of IMP-type metallo-β-lactamase-producing Pseudomonas aeruginosa

Clinical Infectious Diseases

Volumn 37, Issue 1, 2003, Pages 26-32

  Hirakata, Yoichi ^a   Yamaguchi, Toshiyuki ^a,b   Nakano, Michiko ^a   Izumikawa, Koichi ^a   Mine, Mariko ^a   Aoki, Shiho ^a   Kondoh, Akira ^a   Matsuda, Junichi ^a   Hirayama, Mitsukuni ^a   Yanagihara, Katsunori ^a   Miyazaki, Yoshitsugu ^a   Tomono, Kazunori ^a   Yamada, Yasuaki ^a   Kamihira, Shimeru ^a   Kohno, Shigeru ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFOTIAM; CEFTAZIDIME; CEPHEM DERIVATIVE; CIPROFLOXACIN; CORTICOSTEROID; GENTAMICIN; IMIPENEM; INOSINE PHOSPHATE; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATION; CANCER CHEMOTHERAPY; CASE CONTROL STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEATH; FEMALE; GRAM NEGATIVE INFECTION; HOSPITALIZATION; HUMAN; INDWELLING CATHETER; INFECTION COMPLICATION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; RISK FACTOR; URINE;

ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CASE-CONTROL STUDIES; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 0038234897     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/375594     Document Type: Article

References (30)

1. Jones RN, Kirby JT, Beach ML, Biedenbach DJ, Pfaller MA. Geographic variations in activity of broad-spectrum β-lactams against Pseudomonas aeruginosa: summary of the worldwide SENTRY Antimicrobial Surveillance Program (1997-2000). Diagn Microbiol Infect Dis 2002; 43:239-43.
2. Pfaller MA, Jones RN. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from the Americas: resistance implications in the treatment of serious infections. J Antimicrob Chemother 2000; 46(Suppl B):25-37.
3. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47:247-50.
4. Tsakris A, Pournaras S, Woodford N, et al. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000; 38:1290-2.
5. Yano H, Kuga A, Okamoto R, Kitasato H, Kobayashi T, Inoue M. Plasmid-encoded metallo-β-lactamase (IMP-6) conferring resistance to carbapenems, especially meropenem. Antimicrob Agents Chemother 2001; 45:1343-8.
6. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:147-51.
7. Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996; 40:349-53.
8. IMP) in gram-negative rods resistant to broad-spectrum β-lactams. J Clin Microbiol 1996; 34:2909-13.
9. IMP. Antimicrob Agents Chemother 1998; 42:2006-11.
10. IMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995; 39:824-9.
11. IMP. Antimicrob Agents Chemother 1995; 39:1612-5.
12. Kurokawa H, Yagi T, Shibata N, Shibayama K, Arakawa Y. Worldwide proliferation of carbapenem-resistant gram-negative bacteria. Lancet 1999; 354:955.
13. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289:321-31.
14. Bush K, Jacoby G, Medeiros AA. A functional classification for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39:1211-33.
15. Bush K. New β-lactamases in gram-negative bacteria: diversity and impact on the selection of antimicrobial therapy. Clin Infect Dis 2001; 32:1085-9.
16. Woodford N, Palepou M-FI, Babini GS, Bates J, Livermore DM. Carbapenemase-producing Pseudomonas aeruginosa in UK. Lancet 1998; 352:546-7.
17. Cornaglia G, Riccio ML, Mazariol A, Lauretti L, Fontana R, Rossolini GM. Appearance of IMP-1 metallo-β-lactamase in Europe. Lancet 1999; 353:899-900.
18. IMP allelic variants carried by gene cassettes of different phylogeny. Antimicrob Agents Chemother 2000; 44:1229-35.
19. Iyobe S, Kusadokoro H, Ozaki J, et al. Amino acid substitutions in a variant of IMP-1 metallo-β-lactamase. Antimicrob Agents Chemother 2000; 44:2023-7.
20. Lee K, Chong Y, Shin HB, Yong D. Rapid increase of imipenem-hydrolyzing Pseudomonas aeruginosa in a Korean hospital [abstract E-85]. In: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 1998:193.
21. Koh TH, Babini GS, Woodford N, Sing LH, Hall LM, Livermore DM. Carbapenem-hydrolysing IMP-1 β-lactamase in Klebsiella pneumoniae from Singapore. Lancet 1999; 353:2162.
22. Yan J-J, Hsueh P-R, Ko WC, et al. Metallo-β-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001; 45:2224-8.
23. Yan J-J, Ko W-C, Wu J-J. Identification of a plasmid encoding SHV-12, TEM-1, and a variant of IMP-2 metallo-β-lactamase, IMP-8, from a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:2368-71.
24. Chu Y-W, Afzal-Shah M, Houang ETS, et al. IMP-4, a novel metallo-β-lactamase from nosocomial Acinetobacter spp collected in Hong Kong between 1994 and 1998. Antimicrob Agents Chemother 2001; 45:710-4.
25. IMP-7. Antimicrob Agents Chemother 2002; 46:255-8.
26. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999; 43:1584-90.
27. Poirel L, Naas T, Nicolas D, et al. Characterization of VIM-2, a carbapenem-hydrolyzing metallo-β-lactamase and its plasmid- and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44:891-7.
28. NCCLS. Methods for dilution antimicrobial susceptibility testing for bacteria that grow aerobically. 5th ed. Approved standard M7-A5. Villanova, PA: NCCLS, 2001.
29. Rasmussen BA, Bush K. Carbapenem-hydrolyzing β-lactamases. Antimicrob Agents Chemother 1997; 41:223-32.
30. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000; 3:489-95.